VERA 41.16 (+3.18%)
US92337R1014BiotechnologyBiotechnology

Vera Therapeutics (VERA) Stock Highlights

41.16 | +3.18%
2024-10-21 01:52:30
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The companys lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Statistics

Range Today
39.35 41.77
Volume Today 476K
Range 1 Year
9.24 50.78
Volume 1 Year 205.47M
Range 3 Year
5.2 50.78
Volume 3 Year 368.16M
Range 10 Year
5.2 50.78
Volume 10 Year 375.14M

Highlights

Market Capitalization 2.26B (mid)
Floating Shares 40.2M
Current Price 41.16
Price To Earnings -18.24
Price To Book 6.88
Earnings Per Share -2.19
Payout Ratio 0%

Performance

Latest +3.18%
1 Month +2.67%
3 Months +16.77%
6 Months +3.86%
1 Year +282.53%
3 Years +174.22%
5 Years +246.17%
10 Years +246.17%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.